Methods are disclosed for forming bone and/or cartilage in an avian subject. The methods include administering to the avian subject a therapeutically effective amount of a composition comprising avian mesenchymal stem cells and a hydrogel that supports the differentiation of the avian mesenchymal stem cells into cells of an osteogenic and/or condrogenic lineage. In some embodiments, methods are disclosed for repairing a bone defect and preventing infection, such as that associated bone fracture, in an avian subject. The methods include administering locally to the bone defect a composition comprising a therapeutically effective amount of avian mesenchymal stem cells and a hydrogel, such as a methacrylated gelatin hydrogel.
A means for feeder-free culture which can sufficiently maintain the undifferentiation potency of pluripotent stem cells such as iPS cells even without using heterologously derived cells or proteins, is provided. Disclosed are a composition for pluripotent stem cell culture containing activin (preferably, activin A); a medium for pluripotent stem cell culture containing the composition; a method for culturing pluripotent stem cells for proliferating or establishing pluripotent stem cells such as iPS cells (preferably, mammalian iPS cells, and particularly preferably, human iPS cells) while maintaining an undifferentiated condition of the pluripotent stem cells, the method including performing the culture in the presence of activin A; and a method for preparing a pluripotent stem cell clonal population in an undifferentiated condition, the method including culturing undifferentiated pluripotent stem cells such as iPS cells (preferably, mammalian iPS cells, and particularly preferably, human iPS cells) in the presence of activin.
Defibrotide for use in prophylaxis and/or treatment of Graft versus Host Disease (GVHD) in humans is disclosed, preferably in hematopoietic stem cell transplantation (HSCT), more preferably allogeneic hematopoietic stem cell transplantation. Graft versus Host Disease of the invention (GVHD) can be acute aGVHD and/or chronic cGVHD, preferably acute.
Described herein are therapeutic targets expressed in cancer stem cells and methods for treating and diagnosing cancer by targeting such cells with antibodies, compounds, nucleic acid, or other therapeutic agent. In one embodiment described herein, therapeutic agents for the treatment of cancer are provided based on the identification of cancer stem cell targets. The present invention also includes therapeutic targets for cancer therapy and cancer stem cell-targeted therapy. The invention includes the treatment of cancer by the administration of compounds or agents that target cancer stem cells.
The present invention provides a method for preparing cancer stem cells including the step of subjecting normal cells to Ras activation and p53 deficiency; the cancer stem cells prepared by the preparation method; a method for screening a cancer stem cell-targeting substance and a method for screening an anti-cancer substance using the cancer stem cells; a method for treating a cancer comprising administering to a patient the substances obtainable by the screening methods; and a diagnostic method for cancers including the step of detecting proteins specifically expressed in the cancer stem cells or mRNAs of the protein.
This disclosure provides a technology for making a dendritic cell vaccine suitable for high volume manufacturing and distribution. Human stem cells are differentiated in a multi-step protocol to generate cell populations bearing a dendritic cell phenotype. The cells are loaded by pulsing with a specific tumor antigen, or by activation of an inducible transgene. The primed dendritic cells are powerful components of a vaccination strategy to elicit an immune response against tumor-associated antigens like telomerase. Vaccines and reagent combinations prepared according to this invention can be used on demand as off-the-shelf products for treating cancer.
Hepatic progenitors comprise two populations of human hepatic stem cells, primitive and proximal hepatic stem cells, and two populations of committed progenitors, one for biliary cells and one for hepatocytes. Human primitive hepatic stem cells are a very small fraction of the liver cell population and give rise to proximal hepatic stem cells constituting a much larger fraction of the liver. Human proximal hepatic stem cells give rise to biliary and hepatocyte committed progenitors. Primitive and proximal stem cells are the primary stem cells for the human liver. Human primitive hepatic stem cells may be isolated by immunoselection from human livers or culturing human liver cells under conditions which select for a human primitive hepatic stem cell.; Proximal hepatic stem cells may be isolated by immunoselection, or by culturing human liver cells under conditions which include a developmental factor. Proximal hepatic stem cells may also be isolated by culturing colonies comprising a primitive hepatic stem cell under conditions which include a developmental factor. Resulting compositions may be used for treating liver disorders and for producing bioartificial organs.
The disclosure provides methods for increasing genome stability of an embryonic stem (ES) cell or induced pluripotent stem (iPS) cell, increasing telomere length in an ES or iPS cell, or both, for example by contacting an ES or iPS cell with an agent that increases expression of Zscan4 in the cell. Methods for increasing genome stability or increasing telomere length in a population of ES or iPS cells are provided, for example by selecting Zscan4+ ES or iPS cells from the population of ES or iPS cells (which can include both Zscan4+ and Zscan4−ES or iPS cells). Therapeutic methods of using ES or iPS cells expressing Zscan4 are also provided. Further provided are methods of treating cancer by administering a Zscan4 polynucleotide or Zscan4 polypeptide. Also provided are methods of inducing differentiation of isolated ES or iPS cells into germ cells.
PROBLEM TO BE SOLVED: To provide a method for preparing a medical composition for repairing a mammal joint. SOLUTION: A method is used for repairing and/or stabilizing the joint by administering allogenic mesenchymal stem cells to the joint. Moreover, the allogenic mesenchymal stem cells are used in an effective dosage to repair osteoarthritis of the mammal in a site damaged by meniscus injury without any scaffolding. COPYRIGHT: (C)2013,JPO&INPIT